Generation Bio Investigated for Fiduciary Breaches in XOMA Deal, Shareholders to Receive $4.29 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Source: PRnewswire
- Transaction Investigation: The Ademi Firm is investigating Generation Bio's transaction with XOMA Royalty Corporation for potential breaches of fiduciary duty, aiming to ensure the board's accountability to all shareholders.
- Shareholder Benefits: In this transaction, Generation Bio shareholders will receive $4.2913 per share in cash along with a contingent value right, which entitles holders to portions of net cash exceeding $29 million.
- Potential Gains: The contingent value rights also include potential savings from Generation Bio's Cambridge office lease obligations and proceeds from its existing licensing agreement with Moderna, which could provide additional revenue streams for shareholders.
- Competition Restrictions: The transaction agreement imposes significant penalties on Generation Bio for accepting competing bids, raising concerns about whether the board is fulfilling its fiduciary duties to shareholders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
